- Home
- STRM vs BCDA Comparison
STRM vs BCDA Comparison
Compare STRM & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRM
- BCDA
- Stock Information
- Founded
- STRM 1989
- BCDA N/A
- Country
- STRM United States
- BCDA United States
- Employees
- STRM N/A
- BCDA N/A
- Industry
- STRM EDP Services
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- STRM Technology
- BCDA Health Care
- Exchange
- STRM Nasdaq
- BCDA Nasdaq
- Market Cap
- STRM 9.3M
- BCDA 7.9M
- IPO Year
- STRM 1996
- BCDA N/A
- Fundamental
- Price
- STRM $3.15
- BCDA $2.29
- Analyst Decision
- STRM
- BCDA Strong Buy
- Analyst Count
- STRM 0
- BCDA 1
- Target Price
- STRM N/A
- BCDA $25.00
- AVG Volume (30 Days)
- STRM 32.2K
- BCDA 60.3K
- Earning Date
- STRM 12-11-2024
- BCDA 11-13-2024
- Dividend Yield
- STRM N/A
- BCDA N/A
- EPS Growth
- STRM N/A
- BCDA N/A
- EPS
- STRM N/A
- BCDA N/A
- Revenue
- STRM $20,301,000.00
- BCDA $71,000.00
- Revenue This Year
- STRM N/A
- BCDA $6.92
- Revenue Next Year
- STRM $4.04
- BCDA N/A
- P/E Ratio
- STRM N/A
- BCDA N/A
- Revenue Growth
- STRM N/A
- BCDA N/A
- 52 Week Low
- STRM $1.85
- BCDA $1.84
- 52 Week High
- STRM $9.75
- BCDA $10.95
- Technical
- Relative Strength Index (RSI)
- STRM 57.65
- BCDA 49.22
- Support Level
- STRM $2.82
- BCDA $1.97
- Resistance Level
- STRM $3.72
- BCDA $2.18
- Average True Range (ATR)
- STRM 0.36
- BCDA 0.17
- MACD
- STRM 0.12
- BCDA 0.00
- Stochastic Oscillator
- STRM 65.87
- BCDA 61.64
About STRM Streamline Health Solutions Inc.
Streamline Health Solutions Inc provides transformational data-driven solutions for healthcare organizations. It provides computer software-based solutions through its looking glass platform. Its solutions include coding and CDI, coding audit, and financial management solutions. It offers various services, such as custom integration services, training services, electronic image conversion and database monitoring services. It sells its solutions and services in North America to hospitals and health systems, including physician practices, through its direct sales force and its reseller partnerships.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).